NewAmsterdam Pharma Company NV News - NAMS | ADVFN

Register for streaming realtime charts, analysis tools, and prices.

Get Started

Home
Investing
Stocks
USA
NASDAQ
NewAmsterdam Pharma Company NV (NAMS)
NewAmsterdam Pharma Company NV (NAMS) News

NewAmsterdam Pharma Company NV (NAMS)

17.69

0.26

( 1.49% )

Updated: 12:16:35

Delayed by 15 minutes

Empower your portfolio: Real-time discussions and actionable trading ideas.

FeaturedSMX and FinGo Enter Into Collaboration Mandate to Develop a Joint 'Physical to Digital' Platform Service To Enhance Natural Rubber Industry's Ability to Report on Sustainable and Ethical Supply Chains

NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NAARDEN, the Netherlands and MIAMI, Sept. 06, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V...

NewAmsterdam Pharma to Participate in Upcoming Investor Conferences in September

NAARDEN, The Netherlands and MIAMI, Aug. 30, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V...

NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter Financial Results

-- Reported positive topline data from pivotal Phase 3 BROOKLYN trial evaluating obicetrapib in patients with...

NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NAARDEN, The Netherlands and MIAMI, Aug. 02, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V...

NewAmsterdam Pharma Announces Positive Topline Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia

-- Achieved primary endpoint of LS mean reduction in LDL-C on top of maximally tolerated lipid modifying...

NewAmsterdam Pharma to Announce Topline Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia on Monday, July 29, 2024

NAARDEN, the Netherlands and MIAMI, July 26, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V...

NewAmsterdam Pharma Announces Appointments of Mark C. McKenna and Wouter Joustra to its Board of Directors

NAARDEN, The Netherlands and MIAMI, July 18, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V...

NewAmsterdam Pharma Completes Enrollment in Pivotal Phase 3 TANDEM Clinical Trial Evaluating Fixed-Dose Combination of Obicetrapib plus Ezetimibe in Patients with HeFH and/or ASCVD or ASCVD Risk Factors

NAARDEN, The Netherlands and MIAMI, July 08, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V...

NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NAARDEN, The Netherlands and MIAMI, July 03, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V...

NewAmsterdam Pharma Announces Issuance of Composition of Matter Patent for Obicetrapib by the United States Patent and Trademark Office

-- New patent extends patent term for obicetrapib until July 2043 -- NAARDEN, the Netherlands and MIAMI, June...

NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NAARDEN, the Netherlands and MIAMI, June 07, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V...

NewAmsterdam Pharma to Participate in Upcoming Investor Conferences in June

NAARDEN, the Netherlands and MIAMI, May 29, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V...

NewAmsterdam Pharma to Present New Clinical and Preclinical Data Highlighting Obicetrapib’s Impact on Key Risk Factors for Cardiovascular Disease at Upcoming Medical Meetings

-- Presentations include new data from OCEAN, ROSE, and ROSE2 Phase 2 clinical trials, demonstrating...

NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results

-- Enrolled over 9,500 patients in Phase 3 PREVAIL global CVOT-- -- On-track to report topline data from Phase...

1
Next

Monksdream

Monksdream 6 months ago

makinezmoney

makinezmoney 2 years ago

$NAMS: In at $14........ 3k shares

Letssssssssss goooooooooooooooooooooooooooo

https://www.newamsterdampharma.com/

Data presented at #ESCCongress and published in the European Heart Journal show "substantial individual variability in the LDL-c reduction" for patients on inclisiran, highlighting the need for new therapies that can reliably reduce LDL-c levels. https://t.co/7iGv7ESGl4 pic.twitter.com/KI22W5JRs2— NewAmsterdam Pharma Corporation (@NewAmsPharma) January 24, 2023

$12 stop

GO $NAMS

NewAmsterdam Pharma Comp...

Delayed Upgrade Clock